Department of Obstetrics and Gynecology, The Morehouse School of Medicine, Atlanta, Georgia, USA.
Int J Womens Health. 2011;3:185-92. doi: 10.2147/IJWH.S20685. Epub 2011 Jul 12.
An early detection of precursor lesions of cervical cancer will help to eliminate the worldwide burden of cervical cancer.
This exploratory study aimed to identify, by matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS), serum protein profiles that distinguish cervical intraepithelial neoplasia grades CIN 1 or lower (≤CIN 1) from CIN 2+ among 127 women infected with human papillomavirus (HPV) 16. Of these 127 women, 25 and 23 were diagnosed with CIN 2 or CIN 3, respectively (cases), and 79 were diagnosed with ≤CIN 1 (non-cases). Serum protein profiles were generated by MALDI-TOF-MS. A total of 95 m/z peaks were tested for association with case status by two racial groups, African American (AAs) and Caucasian American (CAs).
Overall, 2 protein peaks identified by our study demonstrated higher specificity for identifying CIN 2+ than previously published studies. An increasing intensity of [m/z 4459] was associated with a higher risk of being a case, regardless of race with a specificity of 58% for CIN 2 and a specificity of 75% for CIN 3. An increasing intensity of [m/z 4154] was not only associated with a higher risk of being a case only among CAs, but also had an opposite effect among AAs.
Identification of specific proteins associated with the peaks detected in serum and development of antibody-based tests such as ELISA should lead to the development of race-specific, non-invasive and cost effective screening tests with higher specificity for identifying HPV 16 associated CIN 2+.
早期发现宫颈癌前病变有助于消除全球宫颈癌负担。
本探索性研究旨在通过基质辅助激光解吸/电离(MALDI)飞行时间(TOF)质谱(MS)鉴定出与 HPV16 相关的宫颈上皮内瘤变(CIN)2+区分 CIN1 或更低(≤CIN1)的血清蛋白谱。在 127 名感染 HPV16 的女性中,其中 25 名和 23 名分别诊断为 CIN2 或 CIN3(病例),79 名诊断为≤CIN1(非病例)。采用 MALDI-TOF-MS 生成血清蛋白谱。通过两组,非裔美国人(AA)和高加索裔美国人(CA),共测试了 95 个 m/z 峰与病例状态的相关性。
总的来说,本研究确定的 2 个蛋白峰比以前发表的研究具有更高的特异性,可用于识别 CIN2+。[m/z4459]的强度增加与发生病例的风险增加相关,与种族无关,CIN2 的特异性为 58%,CIN3 的特异性为 75%。[m/z4154]的强度增加不仅与 CA 中病例的风险增加相关,而且在 AA 中也有相反的效果。
鉴定与血清中检测到的峰相关的特定蛋白质,并开发基于抗体的测试,如 ELISA,应导致开发针对种族特异性、非侵入性和具有成本效益的筛查测试,具有更高的特异性,以识别 HPV16 相关的 CIN2+。